BME100 f2014:Group27 L1

BME 100 Fall 2014	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Your name Name: Your name Name: Your name Name: Your name Name: Your name Name: Your name LAB 1 WRITE-UP 1. What are your independent and dependent variables? The independent variables are the amounts of inflammation inducing agent (lipopolysaccharide). The dependent variable is the the amount of inflammatory protein (inflammotin). 2. Describe your experimental design. Give group 1 the 0mg control, group 2 the 10 mg dosage, group 3 the 15 mg dosage, group 4 the 20 mg dosage, and group 5 the 25 mg dosage. The patients will take their dosages for the prescribed amount of time. At the end of the prescription period, we will use an ELISA test to measure the amount of Inflammaotin in each patients blood. a. How many groups? We will have 5 different groups. Our first group will be the control group given 0mg of the inflammation agent. The second group will be given 10mg as this is the lowest dosage known to give results. The third group will be given a 15mg dosage. The fourth a 20mg dosage and the fifth will be given 25mg. These small doses will help determine the minimum amount of the agent is required. b. How many subjects/group? We will have 10 subjects per group for a total of 50 subjects. Each group will consist of 5 males and 5 females to help determine the effects per gender. 3. How will you select your subjects? We would go to 5 different primary care physicians, and at each request for 10 subjects; half male, half female, all 60 years or older. This would give us our total of 50 subjects. 4. What are some of the potential sources of error or biases that could affect your results and how would you control for them? Possible biases include the discrepancy between the kind of people who agree to this study, leading to a less diverse experimental pool. Similarly, a physician's bias may come into play if they recommend the study to certain "favorite" patients and deny others. Ideally, we would be able to personally inquire the patient's participation to take away any bias that another person--the doctor--could add to the process. Additionally, a patient may overtake or undertake their dosage of the drug, leading to poor experimental results. To eliminate the bias that people who agree to this study will be fairly similar, the question could instead be a blind study so that not every one is scared off. This also means that bias is also eliminated among the patient because now they are unaware of the intended results. To control the issue that a patient may undertake or overtake their dosage they will be monitored to make sure they abide by the structure of the experiment. Independent and Dependent Variables Experimental Design Groups Age Number of subjects per group Subject Selection Sources of Error and Bias